ORGANOGENESIS HOLDINGS INC (ORGO)

US68621F1021 - Common Stock

3.05  -0.06 (-1.93%)

After market: 3.05 0 (0%)

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (12/20/2024, 8:00:02 PM)

After market: 3.05 0 (0%)

3.05

-0.06 (-1.93%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%350%
Sales Q2Q%6.12%
CRS27.46
6 Month22%
Overview
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Ins Owners24.91%
Inst Owners47.99%
Market Cap404.37M
Shares132.58M
PE27.73
Fwd PE199.35
Dividend YieldN/A
Analysts82
Short Float %11.39%
Short Ratio11.45
IPO12-02 2016-12-02
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ORGO Daily chart

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 862 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Company Info

ORGANOGENESIS HOLDINGS INC

85 Dan Rd

Canton MASSACHUSETTS 02021

P: 17815750775

CEO: Gary S. Gillheeney Sr.

Employees: 862

Website: https://investors.organogenesis.com

ORGO News

News Imagea month ago - Organogenesis Holdings Inc.Organogenesis Expands Manufacturing Capacity to Support Future Growth

CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...

News Imagea month ago - Organogenesis Holdings Inc.Organogenesis Commends Final LCDs

Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination...

News Imagea month ago - The Motley FoolOrganogenesis (ORGO) Q3 2024 Earnings Call Transcript

ORGO earnings call for the period ending September 30, 2024.

News Imagea month ago - Organogenesis Holdings Inc.Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...

News Imagea month ago - Organogenesis Holdings Inc.Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases...

News Imagea month ago - Organogenesis Holdings Inc.Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...

ORGO Twits

Here you can normally see the latest stock twits on ORGO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example